a cd38-targeting bispecific antibody in the treatment of r/r t-all
Published 6 months ago • 95 plays • Length 2:36Download video MP4
Download video MP3
Similar videos
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl
-
1:59
t-cell engagers vs monoclonal antibodies for the treatment of aml: the influence of cd38 expression
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
1:45
mechanisms of action of cd38 antibodies in myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
0:56
the impact of the addition of anti-cd38 monoclonal antibodies to the frontline treatment of myeloma
-
5:54
how to inhibit cd38 as we age | lps drives cd38 expression | prof covarrubias interview series ep5
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
1:05
where do bispecific antibodies fit into the large cell lymphoma treatment landscape?
-
2:44
dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma
-
6:38
the sequencing of cd19-targeting car-ts and cd20-targeting bispecifics in dlbcl
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
1:13
dual-targeted regimens for the treatment of cll: anti-cd20 antibodies, btki, and bcl2i
-
2:41
cell avidity as a predictor of t-cell efficacy
-
1:21
cd20/cd3 bispecific antibodies in r/r dlbcl: glofitamab and epcoritamab
-
0:45
cys-ser mutation-driven ibrutinib resistance and alternative btki’s under development
-
2:41
an overview of the latest advances in hematology
-
8:57
outcomes of sct in t-all and t-lbl